• Jakob Ledwoch, Jennifer Franke, Edith Lubos, Peter Boekstegers, Miriam Puls, Taoufik Ouarrak, Stephan von Bardeleben, Christian Butter, Joachim Schofer, Ralf Zahn, Hüsseyin Ince, Jochen Senges, and Horst Sievert.
• CardioVascular Center Frankfurt, Seckbacher Landstraße 65, 60389, Frankfurt, Germany.
• Clin Res Cardiol. 2018 Mar 1; 107 (3): 241-248.

AimsThe 6-min walk test (6 MWT) has been established as an important tool for functional assessment in heart failure patients. However, its prognostic impact on the outcome in subjects with mitral regurgitation undergoing transcatheter mitral valve repair is unknown.MethodsThis present work represents a sub-analysis of the German, prospective, multicenter, Transcatheter Mitral Valve Interventions (TRAMI) registry. Of the main study cohort (n = 828) 326 patients underwent 6 MWT prior to the procedure. Patients were assigned to two groups depending on the preprocedural 6 MWT distance using the median (< 200 m [group 1] vs. ≥ 200 m [group 2]).ResultsNo differences regarding procedural success (97 vs. 96%; p = 0.71) and 30-day mortality (3 vs. 4%; p = 0.96) were observed between the groups. With regards to 1-year outcome, patients with a walking distance < 200 m had higher all-cause mortality (26 vs. 14%; p = 0.013) as compared to those with a 6 MWT distance 200 m. After adjustment of baseline risk factors, 6 MWT distance < 200 m still showed a strong trend towards increased 1-year all-cause mortality (HR 1.63, 95% confidence interval 0.96-2.76; p = 0.071).ConclusionsIn the present study preprocedural 6 MWT distance < 200 m showed a strong trend towards increased 1-year mortality in patients undergoing MitraClip implantation.

37 keywords...

hide…